Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045731 | 0.87 | KARS1 (0.40) | ALDH1A1CYP3A4MAPTALOX15LPAR1 | |
| SCHEMBL31045649 | 0.81 | LPAR1 (0.48) | ALDH1A1CYP3A4LPAR1MEN1KMT2A | |
| SCHEMBL31045810 | 0.79 | MEN1 (0.43) | ALDH1A1CYP3A4LPAR1MEN1KMT2A | |
| SCHEMBL31045886 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MAPTLPAR1MEN1KMT2A | |
| SCHEMBL31045683 | 0.78 | PDE4D (0.35) | ALDH1A1CYP3A4MAPTALOX15LPAR1 | |
| SCHEMBL31045728 | 0.77 | MEN1 (0.39) | LPAR1MEN1KMT2AL3MBTL1ACHE | |
| SCHEMBL31045563 | 0.76 | RXRA (0.40) | ALDH1A1CYP3A4MAPTMEN1KMT2A | |
| SCHEMBL31045604 | 0.76 | PDE4B (0.44) | — | |
| SCHEMBL20789752 | 0.75 | MEN1 (0.43) | ALDH1A1LPAR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL14441138 | 0.75 | SMN1; SMN2 (0.41) | ALDH1A1CYP3A4MAPTALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680336-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2024196788-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | ALDH1A1 1304/4885CYP3A4 1503/4885MAPT 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.